Clinical Trials Logo

Malignant Hepatobiliary Neoplasm clinical trials

View clinical trials related to Malignant Hepatobiliary Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06053333 Recruiting - Clinical trials for Malignant Hepatobiliary Neoplasm

Social Determinants of Health in Hepatobiliary Cancer Patients

Start date: July 17, 2023
Phase:
Study type: Observational

This study evaluates barriers to receiving care and risks associated with developing cancer among patients diagnosed with hepatobiliary cancer.

NCT ID: NCT05334069 Recruiting - Melanoma Clinical Trials

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Start date: August 1, 2022
Phase:
Study type: Observational

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

NCT ID: NCT04704661 Recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Start date: August 9, 2021
Phase: Phase 1
Study type: Interventional

The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.

NCT ID: NCT03857958 Recruiting - Clinical trials for Malignant Hepatobiliary Neoplasm

Metal Versus Plastic Stent in Malignant Hilar Biliary Obstruction

Start date: February 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this study was to compare the difference in the stent patency duration between side-by-side fully covered self-expanding metal stents (SEMS) and side-by-side plastic stents in patients with malignant hilar biliary obstruction.